Diazoxide choline controlled release - Soleno Therapeutics
Alternative Names: C601; C602; DCCR; DCCR - Soleno Therapeutics; Diazoxide choline; Diazoxide choline controlled release; Diazoxide-choline-controlled-release-EssentialisLatest Information Update: 02 Jan 2025
At a glance
- Originator Essentialis
- Developer Essentialis; Soleno Therapeutics
- Class Antihyperlipidaemics; Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Chlorobenzenes; Ethanolamines; Obesity therapies; Peripheral vasodilators; Small molecules; Sulfonamides
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Prader-Willi syndrome
- Phase II Hypertriglyceridaemia
- Discontinued Hypoglycaemia; Obesity
Most Recent Events
- 02 Jan 2025 Chemical structure information added.
- 26 Nov 2024 FDA assigns PDUFA action date of (27/03/2025) for Diazoxide choline controlled release for Prader-Willi syndrome (In adolescents, In adults, In children, In the elderly)
- 26 Nov 2024 US FDA extends the review period for the NDA for Diazoxide choline controlled release for Prader-Willi syndrome (In adolescents, In adults, In children, In the elderly)